Pancreatic Cancer Liver Metastases

• Extent and distribution of disease: how many liver lesions are present, and whether disease exists elsewhere

• Response or resistance to systemic treatment: how the cancer has responded to treatment so far

• Pace of progression: whether the disease is changing slowly or quickly

• Technical feasibility of local treatment: whether liver lesions are positioned so ablation, SBRT or surgery is realistic

• Overall health and treatment tolerance: a person's ability to tolerate further treatment

Together, these factors shape which options are realistic for a given case, a judgment that typically comes from specialist review of liver metastases and treatment planning.

How Doctors Monitor Response to Treatment

Response to treatment is tracked with follow-up CT or MRI scans at intervals set by the treating team, based on the treatment given and how the disease is behaving. CA 19-9, a blood tumor marker, is sometimes evaluated alongside imaging as an additional signal, since levels are not reliable in every patient.

Improvement in the liver does not mean all metastatic disease is controlled elsewhere, which is why the overall pattern across monitored sites, not one finding alone, guides treatment decisions.

Prognosis With Pancreatic Cancer Liver Metastases

Survival statistics show how people with pancreatic cancer have fared as a group, but they cannot predict what will happen for one person. SEER data for people diagnosed between 2016 and 2022 show a 5-year relative survival of 3.4 percent for distant-stage pancreatic cancer, a broad category that includes liver metastases; the chart below shows how this compares with earlier-stage disease.